DOXYLAMINE SUCCINATE 10MG, PYRIDOXINE HYDROCHLORIDE 10MG & FOLIC ACID 2.5MG TABLETS are a three-component solid oral formulation containing doxylamine succinate, pyridoxine hydrochloride, and folic acid at defined strengths. The combination brings together ingredients present at different quantities, making accurate dispensing, premix preparation, blend uniformity, and tablet compression important stages of product development. Particular attention is required for the lower-dose folic acid component so that it remains uniformly distributed throughout the tablet blend. For pharmaceutical manufacturers developing a structured PCD Pharma Franchise portfolio, reproducible manufacturing and analytical control are essential for this type of multi-ingredient tablet.
The formulation contains three active pharmaceutical ingredients with different concentrations and material characteristics. Doxylamine succinate and pyridoxine hydrochloride are incorporated at 10 mg each, while folic acid is present at 2.5 mg per tablet. This difference in loading requires a formulation strategy that minimizes segregation and supports consistent distribution.
The excipient system may contain suitable diluents, binders, disintegrants, glidants, and lubricants selected according to the intended manufacturing process. Before finalizing the formulation, compatibility between each active ingredient and the proposed excipients can be assessed through development studies.
Particle size, density, moisture content, flowability, and compressibility are relevant parameters because differences between the three active ingredients can influence powder movement and blending behaviour.
Folic acid represents the lowest-dose active component in the formulation, making its uniform distribution an important manufacturing consideration. Directly adding a small quantity of folic acid to a comparatively larger powder mass may increase the possibility of non-uniform distribution if the process is not properly controlled.
A geometric dilution or controlled premix approach can be used during formulation development. The low-dose component is gradually blended with a suitable carrier before being incorporated into the larger formulation. This approach can improve distribution and reduce concentration differences within the bulk powder.
The sequence of addition, blender capacity, mixing duration, equipment speed, and material loading pattern are established during development. Blend samples may be collected from different locations to assess content uniformity before the material is released for compression.
Once the blend meets the required specifications, it proceeds to tablet compression using suitable tooling and machine settings. The compression process must produce tablets with consistent weight, dimensions, mechanical strength, and disintegration characteristics.
Compression force, turret speed, feeder performance, and lubrication conditions can influence the final tablet characteristics. Excessive compression may produce tablets that are unnecessarily hard, while insufficient compression may result in weak tablets with poor handling properties.
In-process checks can include average tablet weight, individual weight variation, thickness, hardness, friability, and visual appearance. These checks provide continuous feedback during production and help identify process variation before the complete batch is manufactured.
If a film-coating system is included in the final product design, additional parameters such as coating weight gain, spray rate, drying conditions, and appearance are controlled.
Quality control for DOXYLAMINE SUCCINATE 10MG, PYRIDOXINE HYDROCHLORIDE 10MG & FOLIC ACID 2.5MG TABLETS requires analytical methods capable of evaluating the individual active components within the same dosage form.
Finished-product testing may include identification, assay, related substances, uniformity of dosage units, dissolution, friability, and other applicable quality parameters. Analytical procedures should provide adequate specificity so that each active ingredient can be reliably distinguished and quantified.
Particular analytical attention may be given to folic acid because of its lower concentration. Suitable sample preparation and analytical sensitivity help ensure that the low-dose component is accurately evaluated.
In-process and finished-product results are documented as part of the batch-release process, providing traceability from raw-material dispensing through final packaging.
Stability evaluation determines whether the three active ingredients and the tablet formulation remain within their defined specifications throughout the proposed shelf life. Samples can be assessed for assay, degradation products, dissolution, appearance, hardness, friability, and other relevant characteristics.
Moisture exposure may influence the physical properties of the tablet and the stability of certain ingredients. Therefore, packaging selection and environmental control during manufacturing can form an important part of product development.
Stability studies may also evaluate the effect of temperature, humidity, and light under defined conditions. The resulting data can support the selection of appropriate storage conditions and packaging configuration.
Blister or strip packaging may be considered depending on the required barrier properties and product presentation.
The final packaging system should protect the tablets from environmental exposure while maintaining physical integrity during handling and distribution. Packaging development can include evaluation of moisture protection, seal integrity, compatibility, and tablet recovery from the pack.
Accurate batch coding, labeling, and documentation help maintain product traceability throughout the pharmaceutical supply chain. Consistency in pack configuration also supports organized inventory management for distributors and pharmaceutical marketers.
For pharmaceutical companies, DOXYLAMINE SUCCINATE 10MG, PYRIDOXINE HYDROCHLORIDE 10MG & FOLIC ACID 2.5MG TABLETS can be incorporated into a broader PCD Pharma Franchise portfolio when supported by appropriate regulatory authorization, quality specifications, and standardized manufacturing processes. Controlled premixing, reliable compression, sensitive analytical testing, stability monitoring, and protective packaging together provide a structured foundation for consistent pharmaceutical product development.
Doxylamine Succinate 10mg + Pyridoxine HCl 10mg + Folic Acid 2.5mg Tablets with formulation, manufacturing, quality and packaging details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech